Research Brought to Life

Clinical trials are the most important tool we have for improving the survival of patients with cancer. You should discuss with your doctor whether a clinical trial is available and appropriate for you.

Reset
Reset

CCTL019E2301 (LEDA)

A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL). DiseaseFollicular Lymphoma (FL) SummaryThe purpose of this…
Novartis
Read More

ZE46-0134-002

This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukaemia. DiseaseFLT3 mutated Relapsed or…
Read More

TrAVeRse

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse) TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants. The…
Read More

DR-0201-ONC-001

A Multicenter, Multiple Expansion Cohort, Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Multiple Ascending Doses in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma This is a…
Read More

PRIMAVERA

PRIMAVERA (D7230C00001) This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in…
Read More

87801493LYM1001

87801493LYM1001 A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer DiseaseLymphoma, Non-Hodgkin SummaryThe purpose of this study is to characterize safety and…
Read More

INDEPENDENCE

INDEPENDENCE An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)…
Read More

BGB-21447

BGB-21447 Phase 1 Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies DiseaseRelapsed Non-Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Relapsed Chronic Lymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Relapsed Follicular Lymphoma…
Read More

AMLM26/T4 INTERCEPT

AMLM26/T4 INTERCEPT A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – SNDX5613 DiseaseAcute Myeloid Leukaemia SummaryThe ALLG…
Read More

BGB11417-301

BGB11417-301 Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) DiseaseCLL SummaryThe main objective of this study is to compare…
Read More

SKYGLO

SKYGLO An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma DiseaseLarge B-Cell Lymphoma SummaryThe purpose…
Read More

ISB 2001-101

ISB 2001-101 Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma DiseaseRelapsed/Refractory Multiple Myeloma SummaryThis study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of…
Read More

GOlDiLOX

GOlDiLOX A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. DiseaseMantle Cell Lymphoma Mantle Cell Lymphoma Refractory SummaryBrief Summary: The goal…
Read More

IKS03-01

IKS03-01 IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas DiseaseB-cell Non-Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma B-cell Lymphoma SummaryThis first-in-human study will evaluate…
Read More

APTIVATE

APTIVATE A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia…
Read More

DREAMM-20

DREAMM-20 A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in…
Read More

IMpress_001

IMpress_001 Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress) DiseaseMyelodysplastic Syndromes Acute Myeloid Leukemia SummaryThe purpose of this study is to evaluate the…
Read More

CTX112

CTX112 A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies DiseaseB-cell Lymphoma Non-Hodgkin Lymphoma B-cell Malignancy Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Follicular…
Read More

M20-621

M20-621 A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma…
Read More

MagnetisMM-5

MagnetisMM-5 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/​Refractory Multiple Myeloma (MAGNETISMM-5) DiseaseMultiple Myeloma SummaryBrief Summary: The purpose of…
Read More

PRT2527-02

PRT2527-02 A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies DiseaseAggressive B-Cell Non-Hodgkin’s Lymphoma Aggressive B-Cell NHL Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma (MCL) Richter’s Syndrome SummaryThis…
Read More

DR-01-ONC-001

DR-01-ONC-001 A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas DiseaseLGLL – Large Granular Lymphocytic Leukemia Primary Cutaneous T-Cell Lymphoma – Category Primary Cutaneous CD8-Positive…
Read More

80948543LYM1001

80948543LYM1001 A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) DiseaseLymphoma, Non-Hodgkin Leukemia, Lymphocytic,…
Read More

BGB-11417-103

BGB-11417-103 A Study of BGB-11417 in Participants With Myeloid Malignancies DiseaseAcute Myeloid Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm SummaryThe study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and…
Read More

M20-638

M20-638 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) DiseaseFollicular Lymphoma SummaryFollicular…
Read More

MajesTEC-9

MajesTEC-9 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) DiseaseRelapsed or Refractory Multiple Myeloma SummaryThe…
Read More

SLN124-004

SLN124-004 Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera DiseasePolycythemia Vera SummaryThis is a Phase 1/2,…
Read More

DZ2022B0002

DZ2022B0002 A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) DiseaseNon-Hodgkin Lymphoma…
Read More

AMLM26/T5 INTERCEPT

AMLM26/T5 INTERCEPT A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – MBG453 OR MBG453 and Azacitidine DiseaseLeukaemia…
Read More

BLOCK PCNSL (NHL32)

BLOCK PCNSL (NHL32) An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma DiseaseLymphoma (non Hodgkin’s lymphoma) SummaryThe purpose of this study is…
Read More

SUCCESSOR-1 (CA057-001)

SUCCESSOR-1 (CA057-001) A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma…
Read More

ASTX660-03

ASTX660-03 A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) DiseaseRelapsed/Refractory Peripheral T-cell Lymphoma SummaryThe primary purpose…
Read More

BELLWAVE

Bellwave (MK-1026-003) A Phase 2 Study to Evaluate the Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies DiseaseHematologic Malignancies SummaryThe purpose of this study is to evaluate…
Read More

NHL35: ALLG-PACIFIC

NHL35: ALLG-PACIFIC An open label phase 2 study of Pembrolizumab And Chemo-Immunotherapy as FIrst-line therapy for primary mediastinal B-Cell lymphoma DiseaseB-Cell Lymphoma Summary open label phase II study of R-CHOP…
Read More

SNDX-5613-0700

SNDX-5613-0700 A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) Disease Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Mixed Lineage Acute Leukemia…
Read More

EZH-302

EZH-302 A Phase 1b/3 Double Blind Randomized, Active-Controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma DiseaseRelapsed/Refractory Follicular…
Read More

LOXO-BTK-20022

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously…
Read More

BGB-16673-101

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients…
Read More

Epcoritamab

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in…
Read More

AMLM25

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly Acute…
Read More

AMLM22/D2

The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to…
Read More

GCT-3013-01

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Read More

BGB-11417-101

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature…
Read More

Clinical Trial FAQ’s